Astellas Pharma Inc. Receives a Positive CHMP Opinion for EU Marketing Authorisation for FK506 Modified Release as a Once-Daily Immunosuppressant in Organ Transplantation

TOKYO--(BUSINESS WIRE)--Astellas Pharma Inc. (Headquarters: Tokyo, President and CEO: Masafumi Nogimori) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a positive opinion recommending marketing approval of the once-daily immunosuppressant FK506 Modified Release formulation (generic name: tacrolimus) for the prevention of rejection in organ transplantation.